Noxopharm Ltd has released a press release.
September 2022 Quarterly Activities Report and Appendix 4C
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Noxopharm
- Novel Dual-cell Therapy Results in Pancreatic Cancer
- Response to ASX Price Query
- June 2022 Quarterly Activities Report and Appendix 4C
- March 2022 Quarterly Activities Report and Appendix 4C
- FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma Treatment
Later from Noxopharm
- NOX Pipeline Boosted by $1.5M Grant to Hudson Institute
- DARRT-2 Trial Efficacy Phase to Commence
- December 2022 Quarterly Activities Report and Appendix 4C
- Appendix 4D and Half Year 2023 Financial Report
- Noxopharm Announces Novel mRNA Vaccine Enhancer
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm